Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SAN FRANCISCO, Feb. 01, 2017 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the fourth quarter and 2016 after the close of trading on Wednesday, February 15, 2017. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for international callers, using Conference ID: 58707805. A live and archived webcast of the event will be available on the “Investor Relations” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 600,000 patients, accumulating more than 150 million hours of curated heartbeat data within iRhythm’s data repository.
Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected] Media Contact Aaron Murphy (415) 229-3331 [email protected]
